CD22 Antibody (MYG13): sc-7323
- CD22 Antibody (MYG13) is a mouse monoclonal IgG1 κ CD22 antibody, cited in 8 publications, provided at 200 µg/ml
- raised against Raji cells of human origin
- CD22 Antibody (MYG13) is recommended for detection of CD22 of mouse, rat and human origin by WB, IP, IF and FCM
- Anti-CD22 Antibody (MYG13) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for CD22 Antibody (MYG13) for WB applications. These reagents are now offered in bundles with CD22 Antibody (MYG13) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD22 Antibody (MYG13) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD22 in mouse, rat, and human samples by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD22 (MYG13) antibody is available in non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. CD22, also known as B-lymphocyte cell adhesion molecule (BLCAM), sialic acid-binding Ig-like lectin 2 (Siglec-2), and Leu-14, is a type I integral membrane glycoprotein that plays a crucial role in regulating B cell signaling and maintaining immune homeostasis. CD22 is predominantly expressed on B cells, where CD22 functions as a negative regulator of B cell receptor signaling, thereby preventing excessive activation and promoting self-tolerance. CD22 is located on the cell membrane and is also found in a cytoplasmic form during early stages of B cell development, making CD22 a valuable marker for acute lymphocytic leukemia. Alternative splicing of the CD22 gene results in two isoforms, CD22α and CD22β, with CD22β being more prevalent. CD22 can also exist as a heterodimer composed of CD22β and the shorter CD22α isoform, highlighting the complexity of CD22 regulation and function in the immune response.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD22 Antibody (MYG13) References:
- Targeting CD22 for the Treatment of B-Cell Malignancies. | Shah, NN. and Sokol, L. 2021. Immunotargets Ther. 10: 225-236. PMID: 34262884
- The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C. | Pluvinage, JV., et al. 2021. Sci Transl Med. 13: eabg2919. PMID: 34851695
- CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response. | Wu, Z., et al. 2022. Front Immunol. 13: 865596. PMID: 35634306
- The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2-associated multisystem inflammatory syndrome in children. | Benamar, M., et al. 2023. J Clin Invest. 133: PMID: 36282598
- Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. | Pennesi, E., et al. 2024. Haematologica. 109: 3157-3166. PMID: 38186333
- Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. | Aminov, S., et al. 2024. J Clin Invest. 134: PMID: 38376944
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. | Schultz, LM., et al. 2024. Leukemia. 38: 963-968. PMID: 38491306
- Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. | Phely, L., et al. 2024. JAMA Oncol. 10: 821-824. PMID: 38635232
- CD22 blockade aggravates EAE and its role in microglia polarization. | Xiang, W., et al. 2024. CNS Neurosci Ther. 30: e14736. PMID: 38739106
- CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder. | Zhang, W., et al. 2024. J Neuroinflammation. 21: 313. PMID: 39616380
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD22 Antibody (MYG13) | sc-7323 | 200 µg/ml | $322.00 | |||
CD22 Antibody (MYG13): m-IgG Fc BP-HRP Bundle | sc-526498 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD22 Antibody (MYG13): m-IgG1 BP-HRP Bundle | sc-531871 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD22 Antibody (MYG13) AC | sc-7323 AC | 500 µg/ml, 25% agarose | $424.00 | |||
CD22 Antibody (MYG13) HRP | sc-7323 HRP | 200 µg/ml | $322.00 | |||
CD22 Antibody (MYG13) FITC | sc-7323 FITC | 200 µg/ml | $336.00 | |||
CD22 Antibody (MYG13) PE | sc-7323 PE | 200 µg/ml | $349.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 488 | sc-7323 AF488 | 200 µg/ml | $364.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 546 | sc-7323 AF546 | 200 µg/ml | $364.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 594 | sc-7323 AF594 | 200 µg/ml | $364.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 647 | sc-7323 AF647 | 200 µg/ml | $364.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 680 | sc-7323 AF680 | 200 µg/ml | $364.00 | |||
CD22 Antibody (MYG13) Alexa Fluor® 790 | sc-7323 AF790 | 200 µg/ml | $364.00 |